These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9020492)

  • 41. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis.
    Droz JP; Kramar A; Ghosn M; Piot G; Rey A; Theodore C; Wibault P; Court BH; Perrin JL; Travagli JP
    Cancer; 1988 Aug; 62(3):564-8. PubMed ID: 2455591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of pregnancy-specific beta 1-glycoprotein in patients with non-seminomatous testicular germ cell tumors.
    de Bruijn HW; Suurmeijer AJ; Sleijfer DT; Koops HS; Ockhuizen T; Willemse PH; Marrink J
    Eur J Cancer Clin Oncol; 1982 Oct; 18(10):911-6. PubMed ID: 6186495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery.
    Vugrin D; Friedman A; Whitmore WF
    Cancer; 1984 Mar; 53(6):1440-5. PubMed ID: 6198071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
    Neumann A; Keller T; Jocham D; Doehn C
    Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Tumor marker diagnosis in non-seminomatous testicular tumors using human chorionic gonadotropin (HCG) and alpha fetoprotein (AFP)].
    Boewer C; Nawka S; Fleck H; Uibel M; Immer U; Schmidt HE; Herzmann H; Pilgrim G; Ziegenbein R
    Z Urol Nephrol; 1985 Feb; 78(2):77-86. PubMed ID: 2581393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.
    Rosas Plaza X; van Agthoven T; Meijer C; van Vugt MATM; de Jong S; Gietema JA; Looijenga LHJ
    Cells; 2019 Oct; 8(10):. PubMed ID: 31597402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
    Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
    Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Tumor markers as a prognostic factor of the response to treatment in cancer of the testicle].
    Germa Lluch JR; Bastus Piulats R
    Actas Urol Esp; 1987; 11(3):293-8. PubMed ID: 2444075
    [No Abstract]   [Full Text] [Related]  

  • 49. Serum ferritin determinations are of no value in the management of patients with disseminated non-seminomatous germ cell tumors.
    Ockhuizen T; Kok AJ; Sleijfer DT; de Bruijn HW; Koops HS; Marrink J
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):931-4. PubMed ID: 2412831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
    Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
    J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.
    Kawaguchi T; Kumabe T; Kanamori M; Saito R; Yamashita Y; Sonoda Y; Watanabe M; Tominaga T
    J Neurooncol; 2011 Sep; 104(3):779-87. PubMed ID: 21359564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Mann K; Clemm C; Wilmanns W
    Anticancer Res; 1997; 17(4B):3047-9. PubMed ID: 9329598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis.
    Horwich A; Peckham MJ
    Cancer Treat Rep; 1986 Nov; 70(11):1329-31. PubMed ID: 2429765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cisplatin combination chemotherapy for advanced germ-cell testicular tumours.
    Taylor RE; Duncan W; Davey P; Munro AJ; Cornbleet MA
    Br J Urol; 1985 Oct; 57(5):567-73. PubMed ID: 2415203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The management of non-seminomatous germ cell tumours (GCT).
    Paz-Ares L; Lianes P; Cortes-Funes H
    Ann Oncol; 1994 May; 5(5):457-62. PubMed ID: 7521207
    [No Abstract]   [Full Text] [Related]  

  • 56. Marker half-life analysis as a prognostic tool in testicular cancer.
    Lange PH; Vogelzang NJ; Goldman A; Kennedy BJ; Fraley EE
    J Urol; 1982 Oct; 128(4):708-11. PubMed ID: 6183454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tissue alpha-fetoprotein and human chorionic gonadotrophin in non-seminomatous testicular tumours. A comparative study with serum levels.
    Altug MU; Akdas A; Ruacan S; Ozen AH; Remzi D
    Br J Urol; 1987 May; 59(5):458-62. PubMed ID: 2439163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cisplatinum dose dependent response in germ cell cancer evaluated by tumour marker modelling.
    Carl J; Christensen TB; von der Maase H
    Acta Oncol; 1992; 31(7):749-53. PubMed ID: 1282349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A case of advanced testicular seminoma--chemotherapy and serum marker].
    Nakamura K; Hagiwara M; Aikawa A; Deguchi N; Tazaki H; Takeshita E; Ito S
    Gan No Rinsho; 1983 Dec; 29(15):1779-82. PubMed ID: 6199531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers.
    Che Y; Buddensieck C; Albers P; Lusch A; Winter C; Siemer RG; Hiester A
    J Urol; 2022 Mar; 207(3):617-626. PubMed ID: 34694152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.